Pretreatment prognostic factors for children with hepatoblastoma results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1

被引:235
作者
Brown, J
Perilongo, G
Shafford, E
Keeling, J
Pritchard, J
Brock, P
Dicks-Mireaux, C
Phillips, A
Vos, A
Plaschkes, J
机构
[1] No & Yorkshire Clin Trials & Res Unit, Leeds LS16 6QB, W Yorkshire, England
[2] Univ Padua, Dept Paediat, Padua, Italy
[3] St Bartholomews Hosp, Dept Paediat Oncol, London, England
[4] Dept Paediat Pathol, Edinburgh, Midlothian, Scotland
[5] Inst Child Hlth, Dept Surg, London, England
[6] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[7] Kinderchirurg Centrum AMCVU, Amsterdam, Netherlands
[8] Univ Childrens Hosp, Dept Paediat Surg, Bern, Switzerland
关键词
hepatoblastoma; prognostic factors; overall survival; liver tumours; childhood;
D O I
10.1016/S0959-8049(00)00074-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to investigate the prognostic significance of pretreatment patient and tumour characteristics for overall (OS) and event-free (EFS) survival in 154 children affected by hepatoblastoma (HB) in the first prospective liver tumour study run by the International Society of Paediatric Oncology. The pretreatment characteristics studied were age, alpha-fetoprotein, platelet count, histology; from radiology: intrahepatic tumour extension (PRETEXT), lung metastases, enlarged hilar lymph nodes, vena cava or extrahepatic vena porta tumour extension and tumour focality. Five-year OS was 75% (95% confidence interval (CI) 68-82%) and EFS 66% (95% CI 59-74%). Both were univariately associated with PRETEXT and the presence of metastases. Additionally tumour focality and enlargement of hilar lymph nodes at diagnosis were univariately associated with EFS. In multivariate analysis, PRETEXT was the only predictor of OS; PRETEXT and metastases were predictors of EFS. There is a need to investigate further these factors to confirm their validity. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1418 / 1425
页数:8
相关论文
共 25 条
  • [1] [Anonymous], 1992, TNM classification of malignant tumors
  • [2] HEPATOBLASTOMA - THE PROGNOSTIC-SIGNIFICANCE OF HISTOLOGIC TYPE
    CONRAN, RM
    HITCHCOCK, CL
    WACLAWIW, MA
    STOCKER, JT
    ISHAK, KG
    [J]. PEDIATRIC PATHOLOGY, 1992, 12 (02): : 167 - 183
  • [3] EFFECTIVE CISPLATIN (DDP) BASED CHEMOTHERAPY IN THE TREATMENT OF HEPATOBLASTOMA
    DOUGLASS, EC
    GREEN, AA
    WRENN, E
    CHAMPION, J
    SHIPP, M
    PRATT, CB
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1985, 13 (04): : 187 - 190
  • [4] EVANS AE, 1982, CANCER-AM CANCER SOC, V50, P821, DOI 10.1002/1097-0142(19820901)50:5<821::AID-CNCR2820500502>3.0.CO
  • [5] 2-K
  • [6] FIELDING LP, 1992, CANCER, V70, P2367, DOI 10.1002/1097-0142(19921101)70:9<2367::AID-CNCR2820700927>3.0.CO
  • [7] 2-B
  • [8] FINEGOLD MJ, 1985, VIRCHOWS ARCH A, V407, P387
  • [9] Greenberg Mark, 1997, P717
  • [10] GREENWOOD M, 1962, REPORTS PUBLIC HLTH, V33